Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?

ECCO'20 Vienna

Year: 2020
Authors:

S. Shields1, J.P. Seenan1, A. Dunlop2, P. Galloway2, J. Macdonald1

1Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK, 2Department of Biochemistry, Queen Elizabeth University Hospital, Glasgow, UK

P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure

ECCO'20 Vienna

Year: 2020
Authors:

S. Bouri1, J. Geldof1, J. Willsmore2, S. Donnelly2, S. Gabe2, A. Hart1

1St Mark’s Hospital, IBD Unit, London, UK, 2St Mark’s Hospital, Intestinal Failure, London, UK

P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry

ECCO'20 Vienna

Year: 2020
Authors:

A. Hernandez Camba1, L. Arranz1, I. Vera2, D. Carpio3, M. Calafat Sard4, A. Lucendo5, C. Taxonera6, S. Marín7, M.J. Garcia8, G. Suris Marín9, E. Sánchez Rodríguez10, A.Y. Carbajo11, M.L. De Castro12, M. Iborra13, A. Martin-Cardona14, I. Rodríguez Lago15, D. Busquets16, F. Bertoletti17, M. Sierra Ausín18, C. Tardillo1, J. Huguet Malaves19, L. Bujanda20, A. Castaño21, O. Merino22, E. Domènch23, L. Ramos24, ENEIDA Project of GETECCU

1Hosp. Universitario Nuestra Señora de la Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, 2Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain, 3Complexo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain, 4Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 5Hospital General de Tomelloso, Gastroenterology, Tomelloso, Spain, 6Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 7Hospital Reina Sofía, Gastroenterology, Córdoba, Spain, 8Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, 9Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain, 10Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 11Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain, 12Complexo H. Universitario de Vigo, Gastroenterology, Vigo, Spain, 13Hospital Universitari La Fe de Valencia and CIBEREHD, Gastroenterology, Valencia, Spain, 14Hospital Universitari Mútua Terrassa and CIBEREHD, Gastroenterology, Barcelona, Spain, 15Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 16Hospital Universitari de Girona, Gastroenterology, Girona, Spain, 17Hospital de la Sta Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 18Complejo Asistencial Universitario de León, Gastroenterology, León, Spain, 19Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain, 20Hospital Universitario de Donostia- Instituto Biodonostia- Universidad del País Vasco UPV/EHU- and CIBEREHD, Gastroenterology, Donostia, Spain, 21Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain, 22Hospital de Cruces, Gastroenterology, Barakaldo, Spain, 23Hospital Universitario Germans Trias i Pujol and CIBEREHD, Gastroenterology, Badalona, Spain, 24Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain

P585 Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: Preliminary results from the IBD subgroup analysis

ECCO'20 Vienna

Year: 2020
Authors:

A. Aksan1,2,3, H. Işık4, S. Aksan2, D. Tuğal5, A. Dignass6, J.M. Stein2,3,7

1Justus-Liebig-Universität, Institute of Nutritional Science, Giessen, Germany, 2Interdisciplinary Crohn-Colitis Centre Rhein-Main, Clinical and Scientific Research, Frankfurt am Main, Germany, 3J.W. Goethe University, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany, 4Hacettepe University, Institute of Science, Ankara, Turkey, 5Hacettepe University, Institute of Nutritional Science, Ankara, Turkey, 6Agaplesion Markus Krankenhaus, Gastroenterology, Frankfurt am Main, Germany, 7DGD Clinics Sachsenhausen, Gastroenterology and Clinical Nutrition, Frankfurt am Main, Germany

P586 Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

B. GU1, K. Venkatesh2, A.J. Williams3, W. Ng3, C. Corte4, S. Ghaly2, W. Xuan5, S. Paramsothy6, S. Connor3

1University of New South Wales, South Western Sydney Clinical School, Sydney, Australia, 2St Vincent’s Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia, 3Liverpool Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia, 4Royal Prince Alfred Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia, 5Ingham Institute for Applied Medical Research, South Western Sydney Clinical School, Sydney, Australia, 6Concord Repatriation General Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia

P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience

ECCO'20 Vienna

Year: 2020
Authors:

S. Lawrence1, H. Huynh2, W. El-Matary3, J. DeBruyn4, M. Carroll2, E. Wine2, J. Chan1, K. Jacobson1

1University of British Columbia, Department of Pediatric Gastroenterology, Vancouver, Canada, 2University of Alberta, Department of Pediatric Gastroenterology, Edmonton, Canada, 3University of Manitoba, Department of Pediatric Gastroenterology, Winnipeg, Canada, 4University of Calgary, Section of Pediatric Gastroenterology, Calgary, Canada

P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

M. Marino1, R. Domenis2, L. Biribin1, A. Cifù2, L. Navarria1, G. Scardino1, M. Fabris2

1Department of Gastroenterology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, 2Istituto di Patologia Clinica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre

ECCO'20 Vienna

Year: 2020
Authors:

P. HODGES, J. Saunders, F. Betteridge

Department of Gastroenterology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK

P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre

ECCO'20 Vienna

Year: 2020
Authors:

C. Rowan, J. O’Donnell, N. Cullen, A. O’Toole, K. Boland

Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland

P591 Therapeutic management in inflammatory bowel disease: Differences in two IBD inception cohorts: 1991–93 and 2010–11 enrolled in the north-west of Spain

ECCO'20 Vienna

Year: 2020
Authors:

M.L. De Castro Parga, V. Hernández, L. Sanroman, J.R. Pineda, M. Figueira, J. Martinez-Cadilla, S. Pereira, J.I. Rodriguez-Prada

University Hospital Complex of Vigo, Department of Gastroenterology, Vigo, Spain

P592 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice

ECCO'20 Vienna

Year: 2020
Authors:

O. Knyazev, A. Kagramanova, A. Lishchinskaya, A. Parfenov

Moscow Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation

P593 Predictors of steroid-resistance in severe colitis of inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

C. JEMMALI1, A. Labidi2, M.A. Jouini2, M. Hafi2, M. Serghini2, M. Fekih2, J. Boubaker2

1Faculty of Medicine of Tunis, Gastroenterology A Rabta, Tunis, Tunisia, 2Rabta, Gastroenterology A, Tunis, Tunisia

P594 Increased levels of stress, anxiety and depression among patients with CD and UC

ECCO'20 Vienna

Year: 2020
Authors:

E. Laoudi1, D. Papalouka2, M. Gkizis1, G. Kokkotis1, N. Perlepe1, I. Vlachogiannakos3, I. Papakonstantinou2, G. Bamias1

1National and Kapodistrian University of Athens, GI Unit-3rd Academic Department of Internal Medicine- Sotiria Hospital, Athens, Greece, 2Medical School-National and Kapodistrian University of Athens, 2nd Department of Surgery Aretaieion Hospital, Athens, Greece, 3National and Kapodistrian University of Athens- Medical School, Gastroenterology Department of Laiko Hospital, Athens, Greece

P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos

ECCO'20 Vienna

Year: 2020
Authors:

R. Stidham1,2, H. Yao3, S. Bishu1, M. Rice1, J. Gryak3, H.J. Wilkins4, K. Najarian2,3,5

1University of Michigan, Department of Medicine - Division of Gastroenterology and Hepatology, Ann Arbor, USA, 2University of Michigan, Michigan Integrated Center for Health Analytics and Medical Prediction MiCHAMP, Ann Arbor, USA, 3University of Michigan, Department of Computational Medicine and Bioinformatics, Ann Arbor, USA, 4Lycera Corporation, Clinical Development, Plymouth Meeting, USA, 5University of Michigan, Department of Electrical Engineering and Computer Science, Ann Arbor, USA

P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine

ECCO'20 Vienna

Year: 2020
Authors:

S. Timeus1, R. Laoun2

1Tillotts Pharma AG, Drug Safety, Rheinfelden, Switzerland, 2Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland

P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, D. Walker2, K. Winthrop3, M. Genovese4, B. Combe5, Y. Tanaka6, A. Kivitz7, F. Matzkies8, B. Bartok9, L. Ye10, Y. Guo10, C. Tasset1, J. Sundy11, E. Keystone12, R. Westhovens13, W. Rigby14, G. Burmester15

1Galapagos, Clinical Development, Mechelen, Belgium, 2Northumbria Healthcare, Department of Rheumatology, Northumbria, UK, 3Oregon Health and Science University, Department of Rheumatology, Portland, USA, 4Stanford University USA, Immunology and Rheumatology, Palo Alto, USA, 5CHU Montpellier University, Department of Rheumatology, Montpellier, France, 6University of Occupational and Environmental Health Japan, Department of Rheumatology, Kitakyushu, Japan, 7Altoona Center for Clinical Research USA, Clinical Research, Duncansville, USA, 8Gilead Sciences Inc., Medical Affairs, Foster City, CA, USA, 9Gilead Sciences Inc., Clinical development, Foster City, CA, USA, 10Gilead Sciences Inc., Biostatistics, Foster City, CA, USA, 11Gilead Sciences Inc., Clinical research, Foster City, CA, USA, 12Mount Sinai Hospital and University of Toronto Canada, Department of Rheumatology, Toronto, Canada, 13University UZ Leuven, Department of Rheumatology, Leuven, Belgium, 14Dartmouth College, Department of Rheumatology, Lebanon, NH, USA, 15Charité-University Medicine Berlin, Rheumatology and Clinical Immunology, Berlin, Germany

P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019

ECCO'20 Vienna

Year: 2020
Authors:

W.J. Sandborn MD1, J. Panés2, B.E. Sands3, W. Reinisch4, I. Modesto5, C. Su6, F. Steinwurz7, N. Lawendy6, N. Koram5, K. Kwok5, T.V. Jones6, A.J. Thorpe6, D. Quirk6, S. Danese8

1Division of Gastroenterology, University of California, San Diego- La Jolla- California, USA, 2Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain, Spain, 3Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, New York, New York, USA, 4Medical University of Vienna, Vienna, Austria, Austria, 5Pfizer Inc., New York, New York, USA, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Unit of Inflammatory Bowel Disease- Hospital Israelita Albert Einstein, São Paulo, Brazil, Brazil, 8Humanitas University- IBD Center- Division of Gastroenterology, Rozzano, Milan, Italy

P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database

ECCO'20 Vienna

Year: 2020
Authors:

S. Esslinger1, M. Otero-Lobato1, S. Gabriel2, M. Clark3, P. Sheridan2, A. Geldhof1

1Janssen Biologics BV, Medical Affairs, Leiden, The Netherlands, 2Janssen LLC, Research and Development, Horsham, USA, 3Janssen LLC, Research and Development, Springhouse, USA

P600 Vedolizumab dose optimisation: Findings from a Belgian registry

ECCO'20 Vienna

Year: 2020
Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, G. Hantsbarger21, P. Dolin22

1University Hospital CHU of Liège, Gastroenterology, Liege, Belgium, 2Saint Pierre University Hospital, Gastroenterology, Brussels, Belgium, 3Imelda ziekenhuis-, Gastroenterology, Bonheiden, Belgium, 4Hospital CHC, Gastroenterology, Liège, Belgium, 5CHwapi Notre Dame, Gastroenterology, Tournai, Belgium, 6Maria Middelares Medical Centre, Gastroenterology, Ghent, Belgium, 7UZ Brussel- Vrije Universiteit Brussel, Gastroenterology, Brussels, Belgium, 8Ziekenhuis Oost Limburg, Gastroenterology, Genk, Belgium, 9Onze Lieve Vrouwziekenhuis, Gastroenterology, Aalst, Belgium, 10University Hospitals Leuven, Gastroenterology, Leuven, Belgium, 11AZ Groeninge Hospital, Gastroenterology, Kortrijk, Belgium, 12AZ St Lucas, Gastroenterology, Gent, Belgium, 13Hopital Universitaire Erasme, Gastroenterology, Brussels, Belgium, 14Clinique St Pierre, Gastroenterology, Ottignies, Belgium, 15CHU UCL Namur site Sainte Elisabeth, Gastroenterology, Brussels, Belgium, 16AZ Delta, Gastroenterology, Roeselare, Belgium, 17Hospital CHR de la Citadelle, Gastroenterology, Liège, Belgium, 18Jessa Ziekenhuis, Gastroenterology, Hasselt, Belgium, 19CHU Ambroise Paré, Gastroenterology, Mons, Belgium, 20Takeda Pharmaceuticals, Medical Affairs, Brussels, Belgium, 21Takeda Pharmaceuticals, Observational Research Analytics, Boston, USA, 22Takeda Pharmaceuticals, Epidemiology, London, UK

P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

N. Van den Berghe1, B. Verstockt2,3, E. Vandeput2, V. Ballet2, A. Gils1, M. Ferrante2,3, S. Vermeire2,3, D. Thomas1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium